PSYENCE BIOMEDICAL LTD.
Business
PSYENCE BIOMEDICAL LTD. is a life science biotechnology company that develops naturally derived psilocybin products to treat psychological trauma and related disorders in the context of palliative care through its operating subsidiary Biomed II. It offers pharmaceutical‑grade natural psilocybin product candidates (notably PEX010, a 25 mg capsule), psilocybin‑assisted psychotherapy protocols, clinical development services and IP licensing and supply arrangements. The company operates via therapeutic R&D and licensing activities and maintains partnerships with CROs and third‑party suppliers and licensors. Psyence conducts clinical programs and sources product in Australia, the UK, Canada, the US and EU, and distributes for clinical use through licensed suppliers, CRO‑managed trials, clinic sites and special access programs.
Summary from filing dated 2025-06-25
Financials
Latest annual snapshot (FY2025, period end 2025-03-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $1.01M |
| Total assets | $7.32M |
| Total liabilities | $594.4K |
| Stockholders' equity | — |
| Operating cash flow | — |